Action ChemoCentryx - CCXI

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

51,99

Prix Achat

30,00

Prix Vente

51,92

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

51,99

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire THOUSAND OAKS, Calif., Oct. 20, 2022...

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of...

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in...

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced...

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the...

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH PR Newswire THOUSAND OAKS, Calif. and SAN CARLOS, Calif...

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced...

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced...

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in...

ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences

SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

CCXI - Frequently Asked Questions (FAQ)

What is the current ChemoCentryx share price?

The current share price of ChemoCentryx is US$ 51,99

What is the 1 year trading range for ChemoCentryx share price?

ChemoCentryx has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
SPGCSacks Parente Golf Inc	US$ 0,1917 (77,50%)	131,64M
AVDXAvidXchange Holdings Inc	US$ 9,99 (44,99%)	162
OSSOne Stop Systems Inc	US$ 3,79 (41,42%)	174
DMNDamon Inc	US$ 0,2486 (39,12%)	64,12M
ACOGAlpha Cognition Inc	US$ 6,81 (29,71%)	7
ADTXAditxt Inc	US$ 0,0414 (-27,11%)	20,09M
YMABY mAbs Therapeutics Inc	US$ 3,60 (-26,68%)	380
ATXIAvenue Therapeutics Inc	US$ 0,711 (-24,80%)	599
HPHHighest Performances Holdings Inc	US$ 0,1485 (-24,62%)	8,65M
RETOReTo Eco Solutions Inc	US$ 3,21 (-22,46%)	183
SPGCSacks Parente Golf Inc	US$ 0,1917 (77,50%)	131,64M
DMNDamon Inc	US$ 0,2486 (39,12%)	64,12M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8,87 (-2,95%)	23,51M
IPAImmunoPrecise Antibodies Ltd	US$ 0,4073 (12,11%)	21,47M
ADTXAditxt Inc	US$ 0,0414 (-27,11%)	20,09M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ChemoCentryx Inc (CCXI)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

CCXI Dernières nouvelles

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences

CCXI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ChemoCentryx Inc (CCXI) Cours

ChemoCentryx Inc (CCXI)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

CCXI Dernières nouvelles

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences

CCXI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS